1 / 8

Global CINV Existing and Pipeline Drugs Market to Reach US$1.88 billion by 2020

Chemotherapy induced nausea and vomiting (CINV) refers to the nausea and vomiting associated with cancer chemotherapy. Various sources indicate that approximately 70% to 80% cancer patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms. Chemotherapy induced nausea and vomiting is an extremely debilitating condition. Although there are currently a number of drugs available to manage CINV, they do not effectively address the symptoms of this condition. The report on CINV existing and pipeline drugs market offers an insightful and in-depth assessment of the current as well as future market potential of CINV drugs. Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the major currently available drugs extensively studied in the report. The historical market size and forecast for each of these drugs (except for Akynzeo, as the U.S. Food and Drug Administration (FDA) approved it only in October 2014) in terms of revenue (USD Million) has been provided in the report for the period from 2012 to 2020. In addition, the compounded annual growth rate (CAGR) for each of these drugs has been provided in the report for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. The report also studies the CINV patient pool for each of these drugs. The market size and CAGR for Akynzeo have been determined for the years from 2015 to 2020.

kksingha
Download Presentation

Global CINV Existing and Pipeline Drugs Market to Reach US$1.88 billion by 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transparency Market Research CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 Published Date 29-Dec-2014 74 Page Report Request Sample Buy Now Press Release Global CINV Existing and Pipeline Drugs Market to Reach US$1.88 billion by 2020:Transparency Market Research Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. CINV Existing And Pipeline Drugs Market REPORT DESCRIPTION CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 Chemotherapy induced nausea and vomiting (CINV) refers to the nausea and vomiting associated with cancer chemotherapy. Various sources indicate that approximately 70% to 80% cancer patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms. Chemotherapy induced nausea and vomiting is an extremely debilitating condition. Although there are currently a number of drugs available to manage CINV, they do not effectively address the symptoms of this condition. The report on CINV existing and pipeline drugs market offers an insightful and in-depth assessment of the current as well as future market potential of CINV drugs. Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the major currently available drugs extensively studied in the report. The historical market size and forecast for each of these drugs (except for Akynzeo, as the U.S. Food and Drug Administration (FDA) approved it only in October 2014) in terms of revenue (USD Million) has been provided in the report for the period from 2012 to 2020. In addition, the compounded annual growth rate (CAGR) for each of these drugs has been provided in the report for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. The report also studies the CINV patient pool for each of these drugs. The market size and CAGR for Akynzeo have been determined for the years from 2015 to 2020. Browse the full report at http://www.transparencymarketresearch.com/cinv-market.html The report also provides extensive analysis of the pipeline drugs SUSTOL (extended release granisetron injection) and rolapitant, including the status of current clinical trials and future sales projection in terms of USD million. The future sales projection of both these pipeline drugs has also been provided for the North American and European regions. The study also provides estimated patient pool for both these pipeline drugs, broken down by North America and Europe. Related & Recently Published Report by Transparency Market Research Organ Transplant Immunosuppressant Drugs Market : http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html In this research study, the global market for CINV drugs has been geographically segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The CINV drugs market size and forecast in terms of revenue for each region has been provided for the period from 2012 to 2020 along with the CAGR for the forecast period from 2014 to 2020. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities. The market overview chapter provides information such as major subtypes of CINV, the etiology of CINV, the pathogenesis of CINV, major emetogenic chemotherapeutic agents, treatment recommendations for CINV and unmet needs in the CINV market. A section on event impact analysis has also been provided in the market overview chapter of the report on CINV existing and pipeline drugs market. Latest Press Release Of This Report: http://www.transparencymarketresearch.com/pressrelease/cinv-market.htm 2 Transparency Market Research

  3. CINV Existing And Pipeline Drugs Market The report on chemotherapy induced nausea and vomiting drugs market also includes a section on the competitive landscape of the market, wherein the qualitative analysis of leading players in the global CINV drugs market is presented. The report concludes with the profiles of major players in the chemotherapy induced nausea and vomiting drugs market such as GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc. Each company profile comprises information such as company overview, financial overview (selling, general and administrative expenses, research and development expenses and annual revenue for consecutive three years 2011, 2012 and 2013), current and pipeline product portfolio, business strategies and recent developments. Get Sample Report Copy with TOC and Market Research : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776 The global CINV existing and pipeline drugs market is segmented as follows: CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Major Drugs • Aloxi (palonosetron) • Zofran Generic (ondansetron) • Kytril Generic (granisetron) • Emend (aprepitant) • Akynzeo (netupitant-palonosetron) • SUSTOL (extended release granisetron injection) • Rolapitant CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Geography • North America • Europe • Asia-Pacific • Rest of the World (RoW) Latest Article Of This Report:- http://www.transparencymarketresearch.com/article/cinv-market.htm TABLE OF CONTENT 3 Transparency Market Research

  4. CINV Existing And Pipeline Drugs Market Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Assumptions 1.3.2 Sources 1.3.2.1 Secondary Research 1.3.2.2 Primary Research 1.3.3 Models 1.4 List of Abbreviations Chapter 2 Executive Summary 2.1 Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2013 & 2020) 2.2 Global CINV Drugs Market, by Major Drugs, 2013 (USD Million) 2.3 Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2013 & 2020 (Value %) Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview 3.1 Chemotherapy Induced Nausea and Vomiting (CINV) 3.1.1 Aetiology/Causes for CINV 3.1.2 Pathogenesis of CINV 3.1.3 Treatment Recommendations for CINV 3.1.4 Unmet Needs in the CINV Market 3.2 Market Dynamics 3.2.1 Drivers 3.2.1.1 Growing number of patients undergoing chemotherapy 3.2.1.2 Anticipated approval of new CINV drugs during the forecast period from 2014 to 2020 3.2.2 Restraints 3.2.2.1 Patent expirations of major CINV drugs during the projected period 4 Transparency Market Research

  5. CINV Existing And Pipeline Drugs Market 3.2.2.2 Strict regulatory pathway and high cost associated with the new drug discovery and development 3.2.3 Opportunities 3.2.3.1 Emphasis on developing breakthrough therapy for the prevention of CINV such as fixed-dose combination product and other innovative products with enhanced therapeutic efficacy 3.2.3.2 Focusing on developing nations as they present immense market potential for CINV drugs 3.3 Event Impact Analysis Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 – 2020 (USD Million) 4.1 Overview 4.2 CINV Existing Drugs Market 4.2.1 Global CINV Drugs Market Revenue, by Major Drugs, 2012 – 2020 (USD Million) 4.2.2 Global CINV Estimated Patient Pool, by Major Drugs, 2012 – 2020 (Thousands) 4.2.3 Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2013 & 2020 (Value %) 4.2.4 Aloxi (palonosetron) 4.2.4.1 Global Aloxi Market Revenue, 2012 – 2020 (USD Million) 4.2.5 Zofran Generic (ondansetron) 4.2.5.1 Global Zofran Generic Market Revenue, 2012 – 2020 (USD Million) 4.2.6 Kytril Generic (granisetron) 4.2.6.1 Global Kytril Generic Market Revenue, 2012 – 2020 (USD Million) 4.2.7 Emend (aprepitant) 4.2.7.1 Global Emend Market Revenue, 2012 – 2020 (USD Million) 4.2.8 Akynzeo (netupitant-palonosetron FDC) 4.2.8.1 Global Akynzeo Market Revenue, 2015 – 2020 (USD Million) 4.3 CINV Pipeline Drugs Market 4.3.1 SUSTOL (granisetron injection extended release) 4.3.1.1 Global SUSTOL Market Revenue, 2016 – 2020 (USD Million) 4.3.1.2 SWOT Analysis for SUSTOL 4.3.1.3 Overview of SUSTOL Phase III study 4.3.1.3.1 Primary Efficacy Results: Complete Response with Patients Receiving MEC 5 Transparency Market Research

  6. CINV Existing And Pipeline Drugs Market 4.3.1.3.2 Primary Efficacy Results: Complete Response with Patients Receiving HEC 4.3.2 Rolapitant 4.3.2.1 Global Rolapitant Market Revenue, 2015 – 2020 (USD Million) 4.3.2.2 SWOT Analysis for Rolapitant 4.3.2.3 Overview of Rolapitant Efficacy Analysis Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million) 5.1 Overview 5.1.1 Global CINV Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million) 5.1.2 Global CINV Estimated Patient Pool, by Geography, 2012 – 2020 (Thousands) 5.2 North America 5.2.1 North America CINV Drugs Market Revenue, 2012 - 2020 (USD Million) 5.2.2 North America CINV Pipeline Drugs Market Revenue, 2015 – 2020 (USD Million) 5.2.3 North America CINV Estimated Patient Pool, by Pipeline Drug, 2015 – 2020 (Thousands) 5.3 Europe 5.3.1 Europe CINV Drugs Market Revenue, 2012 - 2020 (USD Million) 5.3.2 Europe CINV Pipeline Drugs Market Revenue, 2016 – 2020 (USD Million) 5.3.3 Europe CINV Estimated Patient Pool, by Pipeline Drug, 2016 – 2020 (Thousands) 5.4 Asia-Pacific 5.4.1 Asia-Pacific CINV Drugs Market Revenue, 2012 - 2020 (USD Million) 5.5 Rest of the World (RoW) 5.5.1 RoW CINV Drugs Market Revenue, 2012 - 2020 (USD Million) Chapter 6 Competitive Landscape 6.1 Competitive Landscape Chapter 7 Company Profiles 7.1 GlaxoSmithKline plc 6 Transparency Market Research

  7. CINV Existing And Pipeline Drugs Market 7.1.1 Company Overview 7.1.2 Financial Overview 7.1.3 Product Portfolio 7.1.4 Business Strategies 7.1.5 Recent Developments 7.2 Helsinn Holding S.A. 7.2.1 Company Overview 7.2.2 Financial Overview 7.2.3 Product Portfolio 7.2.4 Business Strategies 7.2.5 Recent Developments 7.3 Heron Therapeutics, Inc. 7.3.1 Company Overview 7.3.2 Financial Overview 7.3.3 Product Portfolio 7.3.4 Business Strategies 7.3.5 Recent Developments 7.4 Merck & Co., Inc. 7.4.1 Company Overview 7.4.2 Financial Overview 7.4.3 Product Portfolio 7.4.4 Business Strategies 7.4.5 Recent Developments 7.5 Tesaro, Inc. 7.5.1 Company Overview 7.5.2 Financial Overview 7.5.3 Product Portfolio 7.5.4 Business Strategies 7 Transparency Market Research

  8. CINV Existing And Pipeline Drugs Market 7.5.5 Recent Developments Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse The Market Research Blog : https://herepharmablog.wordpress.com 8 Transparency Market Research

More Related